{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-035398","form_type":"8-K","ticker":"AIFF","cik":"0000803578","company_name":"FIREFLY NEUROSCIENCE, INC.","filed_at":"2024-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.054510+00:00","generated_at":"2026-05-30T00:04:11.312221+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Firefly Neuroscience Q3 cash $1.2M; partners with Bright Minds, Novartis, Takeda","bullets":["Cash $1.2M as of Sept 30, 2024; shares outstanding 8,503,365 as of Nov 12.","Partnered with Bright Minds, Novartis, Takeda for BNA platform in drug development.","Integrated BNA technology at Neurology Consultants of Dallas; partnered with Zeto for EEG devices.","Appointed Dr. Stella Vnook to Board of Directors.","Completed merger with WaveDancer; listed on Nasdaq under ticker AIFF."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-035398","json":"https://secwatch.observer/filing/0001437749-24-035398.json","markdown":"https://secwatch.observer/filing/0001437749-24-035398.md","text":"https://secwatch.observer/filing/0001437749-24-035398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/803578/000143774924035398/0001437749-24-035398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/803578/000143774924035398/wavd20241112_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:04:11.312221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}